Patrick D. Walsh, Interim President and Chief Executive Officer

Mr. Walsh has been a member of the Board since May 2019. He is President & Managing Member of Diligence Team and Diligence Group LLC, consulting practices he founded and is based in Durham, North Carolina and brings over 35 years of experience in the pharmaceutical industry. From May 2019 to April 2020, He was co-founder and CEO of TriPharm Services, an injectable manufacturing business which was acquired by Alcami. From 2015 to February 2019, Mr. Walsh was the chief executive officer of Avista Pharma, a private equity backed global provider of contract manufacturing, development and analytical testing services to pharmaceutical and biotechnology clients that was acquired by Cambrex. Prior to Avista, from 2010 to 2014, Mr. Walsh was the chief executive officer of AAIPharma Services Corporation in Wilmington, North Carolina, a private equity backed global provider of contract manufacturing services. Mr. Walsh’s earlier career includes serving as chief executive officer of Kadmus Pharmaceuticals, Inc., in Irvine, California, and serving as president and chief operating officer of publicly-traded Gensia-Sicor Pharmaceuticals, Inc which was acquired by Teva for $3.2 billion. Mr. Walsh currently serves as an independent director of the Board of Directors of Avid Bioservices, a publicly-traded company based in Tustin, California and serves on its corporate governance committee and is chair of the compensation committee. He is also an independent director of the Board of Directors of Institute Chemica Emiliano (I.C.E.), a privately held specialty chemical company based in Milan Italy. He is also an Operating Partner (part-time) to healthcare private-equity firm Ampersand Capital, based in Wellesley, Massachusetts.

Stephen P. Carey, Vice President and Chief Financial Officer

Mr. Carey leads the company’s finance, accounting and information technology functions. Mr. Carey joined ANI in May 2016 as an accomplished executive with over 20 years of experience in finance and accounting, including 15 years of experience in the pharmaceutical industry. Previously, Mr. Carey served as Senior Vice President, Controller and Principal Accounting Officer of Par Pharmaceutical Companies, Inc., a generic and specialty pharmaceutical company. During his tenure at Par, Mr. Carey supported the company through significant growth, multiple M&A transactions and a public to private equity transaction. Prior to Par, Mr. Carey held various accounting and finance roles at Schering Plough Corporation (now Merck & Co.). Mr. Carey is a CPA (inactive) and began his career at PricewaterhouseCoopers. Mr. Carey holds a B.S. degree in Accounting from Montclair State University.

James G. Marken, Sr. Vice President, Operations and Product Development

Mr. Marken provides leadership for the production, engineering and logistics functions for the company's multi-site prescription drug, and potent compound facilities in Baudette, Minnesota. Mr. Marken brings over 20 years of pharmaceutical industry experience to his position. Prior to joining ANI Pharmaceuticals in 2007 as General Manager of the Minnesota facilities, he worked for Solvay Pharmaceuticals in various departments including Quality Control, Validation and Manufacturing. Mr. Marken holds a B.S. degree in Chemistry from Bemidji State University.

Robert Schrepfer, Sr. Vice President, Business Development and Specialty Sales

Mr. Schrepfer is responsible for identifying and advancing ANI's product pipeline and contract manufacturing opportunities. Prior to joining ANI, Mr. Schrepfer served as Managing Director and Assistant Portfolio Manager at Healthcare Value Capital, a healthcare investment firm, since 2005. Previously, Mr. Schrepfer was Vice President, Equity Research covering the Major and Specialty Pharmaceuticals sector at Bear Stearns & Cos, Inc. Mr. Schrepfer is a Member of the Health Sector Advisory Council at Duke University where he earned his MBA in Finance and Health Sector Management.